- Home
- BPTH vs DRMA Comparison
BPTH vs DRMA Comparison
Compare BPTH & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- DRMA
- Stock Information
- Founded
- BPTH 2007
- DRMA 2014
- Country
- BPTH United States
- DRMA United States
- Employees
- BPTH N/A
- DRMA N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- BPTH Health Care
- DRMA Health Care
- Exchange
- BPTH Nasdaq
- DRMA Nasdaq
- Market Cap
- BPTH 2.2M
- DRMA 2.0M
- IPO Year
- BPTH N/A
- DRMA 2021
- Fundamental
- Price
- BPTH $0.87
- DRMA $1.42
- Analyst Decision
- BPTH Strong Buy
- DRMA Strong Buy
- Analyst Count
- BPTH 2
- DRMA 1
- Target Price
- BPTH $30.00
- DRMA $6.00
- AVG Volume (30 Days)
- BPTH 81.3K
- DRMA 1.4M
- Earning Date
- BPTH 11-13-2024
- DRMA 11-07-2024
- Dividend Yield
- BPTH N/A
- DRMA N/A
- EPS Growth
- BPTH N/A
- DRMA N/A
- EPS
- BPTH N/A
- DRMA N/A
- Revenue
- BPTH N/A
- DRMA N/A
- Revenue This Year
- BPTH N/A
- DRMA N/A
- Revenue Next Year
- BPTH N/A
- DRMA N/A
- P/E Ratio
- BPTH N/A
- DRMA N/A
- Revenue Growth
- BPTH N/A
- DRMA N/A
- 52 Week Low
- BPTH $0.86
- DRMA $1.29
- 52 Week High
- BPTH $21.60
- DRMA $15.00
- Technical
- Relative Strength Index (RSI)
- BPTH 34.38
- DRMA 41.35
- Support Level
- BPTH $0.86
- DRMA $1.38
- Resistance Level
- BPTH $0.92
- DRMA $1.53
- Average True Range (ATR)
- BPTH 0.06
- DRMA 0.20
- MACD
- BPTH 0.01
- DRMA -0.02
- Stochastic Oscillator
- BPTH 5.79
- DRMA 4.00
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.